Perianal Crohn's Disease
Conditions
Brief summary
The investigators propose to study the safety of autologous mesenchymal stromal cell transfer using a biomatrix (the Gore® Bio-A®; Fistula Plug) in a Phase I study using a single dose of 20 million cells. Twenty adult patients (age 18 years or older) with refractory, complicated perianal fistulizing Crohn's disease will be enrolled. Subjects will undergo standard adjuvant therapy including drainage of infection and placement of a draining seton with continuation of pre-existing anti-Crohn's therapy. Six weeks post placement of the draining seton, the seton will be replaced with the MSC loaded Gore® Bio-A® fistula plug as per current clinical practice. The subjects will be subsequently followed for fistula response and closure for 24 months. This is an autologous product derived from the patient and used only for the same patient.
Interventions
DRUGMSC-AFP
Sponsors
William A. Faubion, M.D.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Males and females 18-65 years of age. * Residents of the United States. * Crohn's disease with single or multiple draining complex perianal fistulae (definition as below) for at least three months despite standard therapy (definition below). * Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, and anti-TNF therapy are permitted. * All patients should have undergone a colonoscopy in last 12 months to rule out malignant or premalignant condition * Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia * Ability to comply with protocol * Competent and able to provide written informed consent * Must have failed standard medical therapy including anti-TNF agents
Exclusion criteria
* Inability to give informed consent. * Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient. * Specific exclusions: Evidence of hepatitis B, C, or HIV * History of cancer including melanoma (with the exception of localized skin cancers) * Investigational drug within thirty (30) days of baseline * A resident outside the United States * Pregnant or breast feeding. * History of clinically significant auto-immunity (other than Crohn's disease) or any previous example of fat-directed autoimmunity * Previous allergic reaction to a perianal fistula plug. * If liposuction is not technically feasible * Allergic to local anesthetics * Pregnant patients or trying to become pregnant. * Non-enterocutaneous tracts (ie recto-vaginal, entero-vesicular)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease. | 2-24 months | The primary endpoint of this study is to determine the safety and feasibility of using adipose derived, autologous mesenchymal stromal cells (MSC) bound to the Gore® Bio-A® Fistula Plug for treatment of refractory CD perianal fistulae. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC | 2-24 months | To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC i) Clinically by drainage assessment and ii) Radiographically by MRI, the gold standard test for assessment of healing. |
Countries
United States
Outcome results
None listed